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Tuberculosis (TB) is an important disease that causes thousands of deaths around the world. Resistance against antitubercular
available drugs has been reported; so, research on new eﬀective antimycobacterial molecules is needed. Antimycobacterial activity
of three lignans and two synthetic hydrazones was assessed against Mycobacterium tuberculosis H37Rv by antimycobacterial
microdilution assay (TEMA). An oxadiazoline (AC451) and a lignan (ethoxycubebin) were the most active compounds (MIC
6.09 and 62.4μM, resp.). Several changes in mycolic acid proﬁle of treated bacteria were detected with both compounds by mass
spectrometryanalysis.Additionally,thelevelofreductionofmycolicacidsinethoxycubebintreatmentwascorrelatedtodisruption
in bacterial morphology.
1.Introduction
Approximately 33% of the human population is infected
with Mycobacterium tuberculosis, and every day 4,200 people
die of tuberculosis around the world. Several facts have
been considered as main factors for pandemic progress
[1]. Antituberculosis drugs were discovered more than 40
years ago, [2, 3] resistant strains have emerged due to
lengthy treatments, and latent and persistent infections have
spread all over the world as population migration has
increased. In addition and as it has been described recently,
“HIV/AIDS continues to fuel tuberculosis epidemic, espe-
cially in Africa” [4]. Under these circumstances, there is an
urgent need to search for new antimycobacterial substances
to be used as templates for drug development so that the
current situation of the disease can be tackled. Moreover,
studies on the mechanism of action of new molecules
can be useful to design more eﬀective antimycobacterial
compounds.
Species of Mycobacterium and related genus synthesize
mycolic acids (MAs), which are important lipid components
of the cell wall (CW), are related to the protection of
M. tuberculosis against dehydration, chemical injury, host
immune system, and entry of hydrophilic antibiotics [5].
Therefore, MAs metabolism is an important target for
Mycobacterium growth inhibition, for example, isoniazid is a
ﬁrst line antitubercular drug that inhibits MAs biosynthesis
[6].
In this paper, we report the antimycobacterial activity
of three lignans and two oxadiazoline derivatives against
M. tuberculosis H37Rv analyzed by mass spectrometry and
transmission electronic microscopy to assess the eﬀect of
the most active molecules on MAs biosynthesis and the
ultrastructural changes of this pathogen.2 Tuberculosis Research and Treatment
2.MaterialsandMethods
2.1.PlantMaterialandCompounds. Leaves of Virolaﬂexuosa
were collected in Puerto Berrio (Antioquia-Colombia) in
February 2007; a voucher was deposited at herbarium of
Universidad de Antioquia (HUA 8967).
2.2. Extract Preparation and Fractionation. Dried and
ground plant material (1.0kg) was extracted by percolation
using hexane and ethanol (EtOH). Extracts were concen-
trated under vacuum, yielding crude extracts (CE) which
were fractionated on a Sephadex LH-20 (Sigma) column
using hexane-CH2Cl2-MeOH (2:1:1, v/v) to obtain several
fractions. Subsequently, fractions were analyzed by 1Ha n d
13C NMR spectroscopy to detect lignans, and ﬁnally lignans
1–3 (70, 40 and 20mg), respectively, were obtained by
column chromatography procedures using silica gel 60H
(Merck) and hexane-EtOAc gradients.
SynthesisofCompound4. 1.2mLaceticanhydridewasadded
to pyridoxal isonicotinoyl hydrazone (35mg, 0.122mmol);
the solution was left to stir at 105◦C for 2h and then worked
up (extraction with CH2Cl2). Solvent removal gave a solid
material,andcolumnchromatographyonsilicagel(hexanes-
EtOAc, 3:2) provided compound 4 after chromatographic
separation (12.14mg, 0.037mmol, 30.3%).
SynthesisofCompound5. 1.5mLaceticanhydridewasadded
to hydroxycinnamaldeh´ ıde benzhydrazone (50mg, 0.198
mmol); the solution was left to stir at 151◦Cf o r3 ha n d
then worked up (extraction with CH2Cl2). Solvent removal
gave a solid material, and column chromatography on silica
gel (hexanes-EtOAc, 97:3) provided compound 5 after
chromatographic separation (14.08mg (0.048mmol, 24%).
1Ha n d13C NMR spectra were recorded on Bruker AMX
300 spectrometer in CDCl3 (Compounds 1, 2,a n d3)o r
DMSO d6 (Compounds 4 and 5).
Compound 4: 1H-NMR: H-5, δ 7.22 (s, 1H); H-10, δ 8.29,
(s, 1H); H-13, δ 7.59, (d, J = 5.4 Hz, 2H); H-14, δ 8.58, (d,
5.4 Hz, 2H); H-16, δ 2.07 (s, 3H); H-17, δ 5.13, (d, 12.9 Hz,
1H); H-17, 5.31, (d, 12.9 Hz, 1H); 19-CH3, δ 1.85, (s, 3H).
13C-NMR: C-5, δ 89.16; C-2, δ 168.94; C-6, δ 130.79; C-7,
δ155.57; C-8, δ 145.94; C-10, δ 149.21; C-11, δ 135.87; C-
12, δ 132.97; C-13, δ 121.46; C-14, δ 152.12; C-16, δ19.27;
18-C=O, δ 171.21; 19-CH3, δ19.99.
Compound 5: 1H-NMR: H-6a, δ 2.20 (m, 1H), 17-CH3, δ
2.22 (s,3 H ) ;H 6 b ,δ 2.35 (m, 1H); H-7, δ 2.72 (m,2 H ) ;H -
5, δ 6.25 (d, J = 2.7 and 5.9 Hz, 1H); H-9 and H-10, δ 7.15
(m, 4H); H- 13 and H-14, δ 7.40 (m, 4H); H-11 and H-15,
δ 7.75 (m, 2H). 13C-NMR: 17-CH3, δ 20.10; C-6, 29,59; C-
7, δ 35,11, C-5, δ 92.74; C-12, δ 125,08; C-11 and C-15, δ
126,53; C-13 and C-14, δ 127,33; C-9 and C-10, δ 128.84 and
δ 128.88; C-8, δ 140,85; C-2, δ 156,51; 18-C=O, δ 171.21.
2.3.OrganismandGrowthConditions. Mycobacteriumtuber-
culosis H37Rv (ATCC 27294) was ﬁrst grown on Lowestein
Jensen(LJ)mediumfor15daysat37◦C.Bacterialsuspension
from LJ cultures were grown in Middlebrock 7H9 broth
(Becton Dickinson) supplemented with 0.2% (by vol.)
glycerol (Sigma), 10% (by vol.) OADC (oleic acid, albumin,
dextrose, catalase; Difco), and 0.05% (by vol.) Tween 80
(Sigma). Cultures were incubated in 200mL ﬂask on a
rotatory shaker at 100rpm and 37◦Cf o r1 2d .
2.4.AntimycobacterialActivity. Antimycobacterialsusceptib-
ility was performed against M. tuberculosis H37Rv by 3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) microdilution method (TEMA assay) as described by
Porrasetal.[7].Minimuminhibitoryconcentration(MIC90)
was deﬁned as the lowest concentration that inhibits 90%
of bacterial growth. Three diﬀerent experiments were con-
ducted in diﬀerent days, and each compound was assessed
in triplicate.
Stock solution of the compounds was dissolved in
DMSO, stored at 4◦C until use, and the ﬁnal concentration
of DMSO in experiments was less than or equal to 1%.
2.5. Mycolic Acid Analysis. M. tuberculosis H37Rv cultures
(50mL, 1:20 dilution of bacterial suspension adjusted 1
McFarland) were grown with or without compounds 3 and
4 at MIC, for 24, 48, and 72h period. Bacterial cultures
were centrifuged for 5min at 4◦C and 1048g, and pellets
were washed 5 times with cacodylate buﬀer (CB, 0.1mol l-1;
pH 7.2). Extraction and diazomethane derivation of mycolic
acids were performed as described [8]. Methyl esters mycolic
extracts (MEMEs) were analyzed by mass spectrometry
(MS). MEMEs were resuspended in CHCl3:ACN (1:1, by
vol.) and injected by means of pneumatically assisted pump
in a mass spectrometer APCI-IT (Agilent series 6300). Mass
s p e c t r aw e r ea c q u i r e di nn e g a t i v em o d ea n ds c a nf r o m2 0 0
to 2000m/z. Three diﬀerent injections of each extract were
carried out and the resulting data normalized and compared
to data previously reported in the literature.
2.6. Transmission Electron Microscopy (TEM). Bacterial cul-
tures were treated, centrifuged, and washed as mentioned
a b o v ei nM Sa n a l y s i s .P e l l e t sw e r eﬁ x e dw i t h2 . 5 %G l u -
taraldehyde, 1% Ruthenium Red and 100mM lysine in
cacodylate buﬀer for 2h at 4◦C. After being washed with the
same buﬀer, they were postﬁxed with 1% osmium tetraoxide
and 0.05% Ruthenium Red for 2h at 4◦C. The cells were
dehydrated in a series of ethanol, embedded in mixture
of spur resin and propylene oxide at diﬀerent proportions
(2:1 and 1:1, by vol) and Spurr resin. Finally, they were
polymerizated for 2d at 68◦C. Thin sections were stained
with toluidine blue and observed under light microscopy.
Ultrathin sections (60–90nm) were stained with uranyl
acetate and lead citrate. Finally, they were analyzed and
photographed in Zeiss EM 109 electron microscope.
2.7. Cytotoxicity Assay. Cytotoxicity was determined accord-
ing to MTT protocol assay described by [9] .T h ec e l ll i n e s
used were VERO and MDBK. The 50% inhibitory concen-
trations (IC50) of the assayed compounds were calculated byTuberculosis Research and Treatment 3
Table 1: Antimycobacterial and cytotoxicity of lignans and oxadia-
zolines.
Compounds MIC90 (μM) IC50 (μM)
VERO MDBK
1 159 ≥698 ≥698
2 169 ≥706 ≥706
3 62,4 203 ≥ 651
4 6,09 — 367
5 81.1 — 9,34 × 10−2
Isoniazid 0,438 — —
Rifampin 0,608 — —
logarithmic regression analysis. Compounds were evaluated
in triplicate.
3. Results andDiscussion
Lignans dihydrocubebin (1), hinokinin (2), and ethoxycube-
bin (3)( Figure 1) were previously isolated by us from Virola
ﬂexuosa (Myristicaceae) and reported for other plants, and
their structural assignments were made by comparision of
nmr spectra and physical properties [8, 10].
Antimycobacterial and citotoxical activities of lignans
and oxadiazolines are reported in Table 1. Compounds 3
and 4 showed the most potent inhibitory eﬀect against M.
tuberculosisH37Rv(MIC,24and2μgmL −1,resp .).H o wev er ,
analogue compounds 2 and 5 were less active. MICs of
referencedrugwereinaccordancewiththeantibioticsuscep-
tibility of the bacterial strain used. All compounds exhibited
low cytotoxic eﬀect compared to their antimycobacterial
activity, with the exception of compound 5, whose MIC90
was similar to IC50.
Due to the promising antimycobacterial activity and
low citotoxicity of compounds 3 and 4, their eﬀect on
mycolic acid biosynthesis and ultrastructure was analyzed.
Mass spectra of MEMEs were similar to spectroscopy data
previously reported for MEMEs from M. tuberculosis H37Rv.
However, there is a diﬀerence between the MS method
employed by us with the one reported by other authors
[11, 12]. This analysis allowed identiﬁcation of alpha, keto,
andmethoxymycolicacidsinthesamplesanalyzed(Table 2).
Additionally, presence of [M++Na] adducts of mycolic acids
was conﬁrmed by means of saturation of MEMEs with
potassium salts as was reported [13].
M E M E ss p e c t r u mo fb a c t e r i at r e a t e dw i t hc o m p o u n d4
for 24h showed an increase ranging from 180 to 480% in
alpha and oxygenated mycolic acids with m/z ≥1225 (MA
chain is equal to or greater than 82 carbons), and it also
showedareductioncloseto50%inalphamycolateswithm/z
≤1189 (Figure 2). At the same time, compound 3 caused a
signiﬁcant reduction in all mycolic acids. However, mycolic
acid proﬁles at 48 and 72h-treatment were similar to the
control (data not shown).
Ultrastructural analysis of bacteria treated with com-
pound 3exhibitedaberrantmorphologywithirregularedges
without disruption of the membrane and the cell wall
Table 2: Mass spectrometry data of MEMEs from M. tuberculosis
H37Rv.
m / zp e a k T y p eo fm y c o l i ca c i d ∗ Carbon number∗
1175 Alpha 78
1189 Alpha 79
1211 — —
1229 Alpha 82
1244 Keto 82
1260 Methoxy 83
1276 Keto 84
∗Class and carbon number of mycolic acids in accordance with Laval et al.
[12].
from 24h to 72h of treatment (Figure 3,i m a g e sa t7 2ho f
treatment not shown). Nevertheless, the morphology of the
bacteria treated with compound 4 was not aﬀected. Some
control bacteria exhibited slight morphological alterations
probably due to centrifugation process.
However, the morphological alterations caused by the
compounds were clearly diﬀerent. In normal and abnormal
cells, the cell wall (cw) was a moderately dense layer. The
plasma membrane (pm) appeared to be composed of a
doublelayerseparatedbyalowdensityspace.Theinnerlayer
here seems to be close together to bacterial cytoplasm, and
the outer layer of the plasma membrane adhered closely to
the cell wall. Additionally, TEM analysis of M tuberculosis
bacteria showed similar lamellar structures to mesosome
(m). In Figure 3(a), the plasma membrane is indicated with
a black arrow head. Besides, some globules of various sizes
in the cytoplasm, probably containing residual material
from the culture, were observed. In Figure 3(b), in the
region indicated by small arrows, the cytoplasm is hardly
transformed and its shape is very irregular and disorganized.
In the present study, we assessed antimycobacterial
activity of 3 lignans and 2 synthetic oxadiazolines against
M. tuberculosis H37Rv in order to ﬁnd new substances
active on mycolic acids biosynthesis. As shown in Table 1,
compound 3 was the most active lignan tested. In this type
of compound, the presence of an ethoxy substituent seems
crucial for the activity, further evidenced by the diﬀerence
in activity between compounds 2 and 3. Despite the absence
of a furan ring in compound 1, no signiﬁcant diﬀerence
was between the two compounds 1 and 2, which suggests
the importance of dibenzyl-methylene-dioxy butane moiety
for the activity of these types of compounds. These lignans
are promising since low levels of citotoxicity were observed.
Additionally, antigenotoxic eﬀect of hinokinin has been
reported previously [14].
Oxadiazoline4wasthemostactivecompoundagainstM.
tuberculosis and had the lowest cytotoxicity because MIC90
was 60 times lower than IC50. Other studies report oxadia-
zolines with a pyridine system similar to 4 with promising
antimycobacterial activity in vitro [15, 16]. Treatment of
M. tuberculosis H37Rv with 4 for 24h exhibited alteration
in MAs proﬁles, especially enhanced levels of keto and
methoxy MAs. However, TEM analysis of bacteria treated
with 4 displayed normal morphology. It seems possible that4 Tuberculosis Research and Treatment
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Figure 1: Lignans from V. ﬂexuosa (1,2, and 3) and synthetic oxadiazolines (4and 5).
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Figure 2: Mass spectrum of MEMEs from M. tuberculosis H37Rv
cultures treated with ethoxycubebin (3) and AC451 (4)a t2 4h .
over production of some MAs is a mechanism to overcome
the eﬀects caused by this compound on MAs metabolism,
and can be related to the maintenance of normal bacterial
morphology despite of treatment with compound 4. There
is evidence that some mutant and recombinant strains
of M. tuberculosis producing higher proportions of some
oxygenated MAs do not present aberrant morphology, as it
happened in bacteria treated with 4 [17].
On the other hand, reduced levels of all MAs observed in
M. tuberculosis treated with lignan 3 for 24h can be related
to an abnormal composition of the cell wall, and, therefore,
caused aberrant bacterial morphology evidenced in the same
treatment from 24h to 72h. Similar eﬀects on mycolic
acid biosynthesis and ultrastructural alterations have been
reported in M. tuberculosis and M. aurum cultures treated
with isoniazid, an antitubercular prodrug that inhibits
mycolic acid biosynthesis [18]. To date, there are no reports
on monofuranic lignans with eﬀect against mycolic acid
biosynthesis.
As we mentioned above, alterations in MAs proﬁles
were evidenced at 24h of treatment with compounds 3
and 4.H o w e v e r ,m a s ss p e c t r ao fM E M E sa t4 8a n d7 2ho f
both treatments showed MAs proﬁles similar to the control.
This may mean that bacteria are restoring normal levels of
MAs. Nevertheless, in the case of treatment with 3,a b e r r a n t
morphology was also evidenced at 72h of treatment despite
of MAs restoring proﬁles. This is due to a reversion of a
cell wall deﬁcient form, which is a complex process that in
most of the cases cannot be accomplished even under ideal
conditions [19].Tuberculosis Research and Treatment 5
0.25μm
(a)
0.25μm
(b)
Figure 3: TEM images of M. tuberculosis H37Rv exposed to compound 3 at MIC for 24h (b) and control (a). Plasma membrane (pm). Cell
wall (cw). Mesosome (m). Bar: 13.5mm.
Summarizing, we found lignan ethoxycubebin and oxa-
diazoline AC451 promising antimycobacterial compounds
both having an eﬀect on mycolic acid metabolism of
M. tuberculosis H37Rv. These compounds can be useful
templates for the development of more eﬀective antimy-
cobacterial derivatives that may be used in the future as
antitubercular drugs. Also studies on the mechanism of
action of these compounds can be useful to understand the
metabolic processes related to MAs biosynthesis.
4. Conclusions
This paper reports antimycobacterial activity of two sub-
stances with eﬀect on an important metabolic pathway of
M. tuberculosis, that is, mycolic acid biosynthesis. These
ﬁndings show that AC451 and ethoxycubebin are promising
antimycobacterials aﬀecting mycolic acid metabolism. These
molecules are chemical templates to obtain more potent
derivatives.
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